Athenex Inc. (ATNX)

Business: Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

IPO Date: 14-Jun-2017

Chairman & CEO: Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.

COO & Pres of Athenex Pharmaceutical Division: Mr. Jeffrey M. Yordon

Listing: NASDAQ: ATNX

Country: United States

Headquarters: Buffalo, NY

Website: https://www.athenex.com

Market cap: $48.42 Mln

Revenue (TTM): $108.88 Mln

Earnings (TTM): $-192.14 Mln

Cash: $37.46 Mln

Total Debt: $133.74 Mln

Insider's Holding: 13.19%

Liquidity: Low

52 Week range: $0.41 - 4.53

Shares outstanding: 111,830,000

8 Years Aggregate:

• CFO: $-655.43 Mln
• EBITDA: $-813.53 Mln
• Net Profit: $-876.62 Mln